World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
32058
World Ranking
12599
National Ranking
517

Overview

Jordan J. Feld is affiliated with the University Health Network in Canada and has a research profile primarily centered on medicine, with a focus on epidemiology, hepatology, infectious diseases, immunology, and oncology.

Their frequent publication venues include:

  • Journal of Hepatology
  • Canadian Liver Journal
  • Journal of Viral Hepatitis
  • Hepatology
  • Clinical Infectious Diseases

Jordan J. Feld's research topics cover several areas within liver disease and viral infections, specifically:

  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Hepatitis Viruses Studies and Epidemiology
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research

Among the recent papers authored by Jordan J. Feld are:

  • Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial, 2021, The Lancet Respiratory Medicine

Frequent co-authors in their collaborative research include:

  • Harry L.A. Janssen
  • Bettina E. Hansen
  • Mia J. Biondi
  • Adam J. Gehring
  • Milan J. Sonneveld

The intersection of Jordan J. Feld's work is largely focused on viral hepatitis and liver diseases, where they contribute to epidemiological studies and clinical research. Their involvement spans several subfields, with notable emphasis on epidemiology and hepatology.

The work also encompasses research around SARS-CoV-2 and COVID-19, particularly with clinical trials related to interferon treatments in outpatient settings. This indicates active participation in infectious disease research alongside chronic liver conditions.

Best Publications

  • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

    Adriaan J. van der Meer;Bart J. Veldt;Jordan J. Feld;Heiner Wedemeyer

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Mechanism of action of interferon and ribavirin in treatment of hepatitis C

    Jordan J. Feld;Jay H. Hoofnagle

  • Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

    Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    Jordan J. Feld;Kris V. Kowdley;Eoin Coakley;Samuel Sigal

  • Residual NADPH oxidase and survival in chronic granulomatous disease.

    Douglas B. Kuhns;W. Gregory Alvord;Theo Heller;Jordan J. Feld

  • Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral Infection

    Limin Chen;Ivan Borozan;Jordan Feld;Jing Sun

  • Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

    Graham S Cooke;Isabelle Andrieux-Meyer;Tanya L Applegate;Rifat Atun

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Extrahepatic Morbidity and Mortality of Chronic Hepatitis C

    Francesco Negro;Daniel Forton;Antonio Craxì;Mark S. Sulkowski

  • Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

    Jordan J. Feld;Huong Dinh;Tamara Arenovich;Victoria A. Marcus

  • From non-A, non-B hepatitis to hepatitis C virus cure

    Jean Michel Pawlotsky;Jean Michel Pawlotsky;Jordan J. Feld;Stefan Zeuzem;Jay H. Hoofnagle

  • Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis

    R. Loomba;G. Lutchman;D. E. Kleiner;M. Ricks

  • Increased caffeine consumption is associated with reduced hepatic fibrosis

    Apurva A. Modi;Jordan J. Feld;Jordan J. Feld;Yoon Park;David E. Kleiner

  • Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

    Golo Ahlenstiel;Rachel H. Titerence;Christopher Koh;Birgit Edlich

  • Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response†

    Jordan J. Feld;Santosh Nanda;Ying Huang;Weiping Chen

  • Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

    George N. Ioannou;George N. Ioannou;Lauren A. Beste;Pamela K. Green;Amit G. Singal

  • Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.

    K. Rajender Reddy;Marc Bourlière;Mark Sulkowski;Masao Omata

  • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

    Jason Grebely;Olav Dalgard;Brian Conway;Evan B Cunningham

  • Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

    Ira M. Jacobson;Ira M. Jacobson;Eric Lawitz;Edward J. Gane;Bernard E. Willems

Frequent Co-Authors

Gregory J. Dore
Gregory J. Dore University of New South Wales
Harry L.A. Janssen
Harry L.A. Janssen Erasmus University Rotterdam
Margaret Hellard
Margaret Hellard Burnet Institute
Gail V. Matthews
Gail V. Matthews University of New South Wales
Jason Grebely
Jason Grebely University of New South Wales
Edward Gane
Edward Gane Auckland City Hospital
Janaki Amin
Janaki Amin Macquarie University
Kyong-Mi Chang
Kyong-Mi Chang University of Pennsylvania
Adrian M. Di Bisceglie
Adrian M. Di Bisceglie Saint Louis University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in pathways related to medicine but seek more flexible study options, there are numerous online degrees and certifications to consider. For aspiring nurses, affordability is a key concern—explore the cheapest rn to bsn programs to transition from Registered Nurse to Bachelor of Science in Nursing without incurring heavy debt.

Those from non-nursing backgrounds can fast-track a nursing career through direct entry msn programs, allowing graduates to gain advanced standing and leadership roles in the field. Additionally, many look for flexible options and higher acceptance rates; online adn programs for non nurses offer an accessible entry point into nursing.

For those interested in the administrative side of healthcare, accredited programs in medical billing and coding offer strong job prospects. Find programs that fit your budget by checking medical billing and coding schools that accept financial aid. These options make healthcare careers more accessible and diverse for students with varied backgrounds and goals.

Best Scientists Citing Jordan J. Feld

Trending Scientists

Recently Published Articles